Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293163 · ClinicalTrials.gov registry record · Phase 4
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT00293163 is a Phase 4 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 120 participants.
The verdict
NCT00293163, a Phase 4 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
To assess the likelihood of keloid and scar formation, pigmentation disorders and hypersensitivity reactions in patients with skin of color undergoing correction of facial soft tissue contour deficiencies with Hylaform, Hylaform Plus or Captique.
Interventions
- DEVICE Hylaform, Hylaform Plus (hylan B gel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293163
The ClinicalTrials.gov registry entry for NCT00293163 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hylaform, Hylaform Plus (hylan B gel) is the first listed.
NCT00293163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293163 about?
NCT00293163 is a clinical study titled "A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.". To assess the likelihood of keloid and scar formation, pigmentation disorders and hypersensitivity reactions in patients with skin of color undergoing correction of facial soft tissue contour deficiencies with Hylaform, Hylaform Plus or Captique.
What is the current status of trial NCT00293163?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2006-02. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00293163?
The interventions under investigation include: Hylaform, Hylaform Plus (hylan B gel) (DEVICE).
Who is sponsoring clinical trial NCT00293163?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.